Hints and tips:
Related Special Reports
Related Topics
...Pfizer products such as Paxlovid, combined Covid and flu test Lucira, and recently approved migraine nasal spray Zavzpret will be available on the site....
...Pfizer said: “We are confident in our IP position around Comirnaty and intend to vigorously defend against these claims.”...
...Pfizer is gearing up to launch its first-ever gene therapy at a list price of $3.5mn, after US regulators approved the treatment for a rare blood clotting disorder on Friday....
...But, 10 years this month after Pfizer arrived on the scene, the Frenchman has a fresh challenge: persuading investors that AstraZeneca’s best days are not behind it....
...BioNTech and Pfizer have said the patents are invalid....
...Pfizer reported dwindling Covid-19 revenues and weak sales from other products on Tuesday, as it notched a steep drop in sales in 2023....
...Read more on Pfizer here...
...Data on Pfizer’s once-daily oral pill is expected in the first half of 2024. Its shares fell 4.3 per cent lower before the open in New York. Read more on Pfizer here...
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...Andrea Chiarello, Pfizer’s head of EU government affairs, said drugmakers needed more encouragement to discover new antimicrobials and develop drugs....
...Pfizer swung to a loss in the third quarter after a $5.6bn inventory write-off related to its Covid-19 antiviral and vaccine....
...Pfizer: The pharmaceutical company is expected to report that quarterly revenue declined 23.4 per cent from the same period last year to $14bn, according to LSEG, as the company faces weak demand for its...
...Pfizer revised its full-year revenue guidance to a range between $58bn and $61bn, down from $67bn-$70bn, “solely due to Covid products”, it said....
...wants a pivot in the biotech’s sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer...
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...This included a Merck agreement with Daiichi Sankyo worth up to $22bn, Pfizer’s $43bn acquisition of lossmaking Seagen and AbbVie’s $10.1bn acquisition of ImmunoGen....
...Companies: Pfizer is the latest pharmaceutical company to report first-quarter revenue....
...Pfizer’s revenue more than halved in the second quarter, after demand for its Covid-19 products fell sharply....
...Haleon was born as a joint venture between Pfizer and GSK in 2019 that sat within GSK, before it was spun off via a UK listing in 2022, leaving GSK and Pfizer with 13.5 per cent and 32 per cent of the business...
...GSK secured approval for Arexvy from the US Food and Drug Administration at the start of May, almost a month before Pfizer’s Abrysvo....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
International Edition